

Press Release – Basel, Switzerland December 7<sup>th</sup> 2005

## **Neurocrine takes delivery of Genedata's Computational High Throughput Gene Expression Analysis System**

- **Genedata's computational solution for drug discovery used to scale-up gene expression data analysis capabilities**
- **High throughput integration with Affymetrix GCOS**
- **South San Francisco-based team will provide local support**

**Basel, Switzerland** – Genedata announces that biopharmaceutical company Neurocrine Biosciences has licensed the gene expression analysis system Genedata Expressionist® for biomarker discovery and in-silico prediction and integrated it with Neurocrine's research informatics infrastructure. Scientists at Neurocrine will use Expressionist in its pre-clinical discovery program, which focuses on neurological and endocrine-related diseases and disorders.

"Genedata's software deployment plan extends to on-site training in the system's powerful high throughput functionalities", explained Bill Wilson, Head of IT at Neurocrine. "Scientists at Neurocrine have already used Expressionist to process and evaluate over 1500 GeneChips®, thus preparing the data for detailed expression analysis".

High throughput data processing is achieved using Expressionist's GCOS Monitor, a production mode processing and database tool that is closely integrated with Affymetrix GCOS (GeneChip® Operating Software).

"We are pleased to support Neurocrine in their research efforts", says Matthew Trunnell, Managing Director USA, Genedata Inc. Large-scale analysis of gene expression data poses significant technical challenges. Expressionist has been developed for high throughput applications and offers standardized, automated workflows for processing, analyzing and managing experimental transcriptomics, proteomics and metabolomics data.

### **Contact Genedata's South San Francisco team:**

Genedata Inc.

601 Gateway Boulevard, Suite 610, South San Francisco, CA 94080

Tel. +1 650 246 3888 / Fax +1 650 246 3887

---

#### **Public relations contacts**

Genedata AG.

Dr. Tobe Freeman

Public Relations

Phone +41 61 697 8510

Fax +41 61 697 7244

tobe.freeman@genedata.com

www.genedata.com

Neurocrine Biosciences, Inc.

Claudia Woodworth

Investor Relations

Phone +1 858 617 7600

Fax +1 858 617 7601

ir@neurocrine.com

www.neurocrine.com

**About Genedata**

Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia). For more information about Genedata, please visit: [www.genedata.com](http://www.genedata.com).

**About Neurocrine Biosciences**

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders, pain, and autoimmunity. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at <http://www.neurocrine.com>.

---

**Disclaimer**

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.